Hello and welcome back to one more interesting article wherein we’ll discuss Dr Lal Pathlabs share which was analysed earlier and has achieved the target predicted by us in a span of 5 sessions.
Let’s check the parameters which helped Dr Lal Pathlabs share to achieve its total target of 24% approximately in 27 trading sessions.
BUSINESS ANALYSIS FOR TARGET ACHIEVEMENT
The company conducted 11.4 lakh RTPCR tests and served around 7.1 million patients in these challenging times.
Dr Lal Pathlabs acquired Suburban Diagnostics in an all cash deal with an enterprise value of ₹ 925 Cr and a market cap of ₹ 1,150 Cr which has a great presence in western India.
To strengthen the business in south and western parts of India, the company has launched a new reference lab at pilot phase in Bengaluru and also 6 new satellite labs in the region across six different cities.
Dr Lal Pathlabs is expecting non covid business to grow atleast 14-15% in financial year 2022.
The company is a firm believer that the future of healthcare business is going to revolve around “PHYGITAL” patient journey, which is a combination of physical and digital infrastructure. Hence, the company is betting on technology investments and is not worrying for immediate returns.
FINANCIAL ANALYSIS FOR TARGET ACHIEVEMENT
Figures in Rs. Crores
|Quarterly Results||Jun 2019||Sep 2019||Dec 2019||Mar 2020||Jun 2020||Sep 2020||Dec 2020||Mar 2021||Jun 2021||Sep 2021|
|Profit before tax||89||102||73||45||38||117||129||111||179||131|
|EPS in Rs||7.06||9.66||6.49||3.9||3.41||10.23||11.34||10.01||15.74||11.4|
For the quarter ended 30-09-2021, the company reported a sales of ₹ 498 Cr which is an increase of 13% from the sales registered in the year ago period.
Expense has reduced from the previous quarter which has also impacted the sales of the company.
In quarter ended 30-09-21, the net profit is consolidating in the range of ₹ 83 Cr to ₹ 131 Cr.
Reserves have increased exponentially and there is a great interest shown by the investors in Dr Lal Pathlabs share.
In the quarter ended 30-09-21, the company has borrowed ₹ 41 Cr which could be due to the acquisition, the company has done recently.
Figures in Rs. Crores
|Balance Sheet||Mar 2012||Mar 2013||Mar 2014||Mar 2015||Mar 2016||Mar 2017||Mar 2018||Mar 2019||Mar 2020||Mar 2021||Sep 2021|
SHARE HOLDING SYNOPSIS
|Share Holding||Mar 2019||Jun 2019||Sep 2019||Dec 2019||Mar 2020||Jun 2020||Sep 2020||Dec 2020||Mar 2021||Jun 2021||Sep 2021|
Promoters have maintained their position in this stock with a whopping 55.23%.
FIIs have increased their stake in this company, but the retail investors are reducing their interest in the stock which is not a sign of great concern.
Now, let’s deep dive into the technicalities of Dr Lal Pathlabs share.
CHART PATTERN ANALYSIS
In the previous analysis, we did highlight the formation of the cup and handle pattern.
Click here for previous analysis on Dr Lal Pathlabs share.
Dr Lal Pathlabs share did achieve its target of ₹ 3,880 and rallied till ₹ 4,246 showcasing a target achievement of 24%.